Osteoarthritis and Bone Disorders News

Results published in Arthritis Care & Research showed patients with knee osteoarthritis who had sufficient vitamin K and vitamin D status experienced better lower extremity function.

Patients with knee osteoarthritis who do not meet minimum performance thresholds on clinical tests of physical function may have inadequate physical ability to walk 6,000 steps or more a day, results showed.

Results from this study indicated there was a significant increase in joint replacements in New Zealand for patients with osteoarthritis between 1999 to 2015. However, apart from elbow replacements, joint replacement rates did not decline for patients with rheumatoid arthritis.

PHILADELPHIA — In this video exclusive, Neil C. Binkley, MD, professor in the divisions of geriatrics and endocrinology, associate director of the Institute on Aging and co-director or the Osteoporosis Clinical Center and Research Program at the University of Wisconsin-Madison, discusses the most recent medications available for treatment of osteoporosis.

A primary care group intervention for patients with osteoarthritis yielded improvements in hand function, activity restrictions and self-reported health, according to findings.

PHILADELPHIA — “Dysmobility” implies difficulty with standing and walking that can lead to a fall and often a fracture. In this video exclusive, Neil C. Binkley, MD, professor in the divisions of geriatrics and endocrinology, associate director of the Institute on Aging and co-director or the Osteoporosis Clinical Center and Research Program at the University of Wisconsin-Madison, discusses the shift in thinking about osteoporosis to thinking about a dysmobility syndrome.

Among healthy men aged 25 to 45 years, higher levels of bone turnover markers predict greater decreases in areal bone mineral density 12 years later, according to a population-based study conducted in Belgium.

Amgen announced the FDA has accepted for review the supplemental biologics license application for Prolia in the treatment of glucocorticoid-induced osteoporosis.

The FDA approved triamcinolone acetonide intra-articular injection for the treatment of patients with osteoarthritis knee pain, according to the drug’s manufacturer.

Obesity was associated with an increased risk of late-life mobility limitation among older women who underwent total knee or total hip replacement for osteoarthritis, according to recently published study results.